STATENS SERUM INSTITUT Patent applications |
Patent application number | Title | Published |
20140275478 | Vaccines against Chlamydia sp. - The present invention describes an efficient vaccine against a | 09-18-2014 |
20140205656 | MODIFIED CATIONIC LIPOSOME ADJUVANTS - The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of antibodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and | 07-24-2014 |
20140170182 | PRODUCTION OF A CYSTEINE RICH PROTEIN - The present invention relates to a method for the production of correctly folded Pfs48/45. This is achieved in the | 06-19-2014 |
20140154696 | PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGI - Dermatophytes which belong to one of the three genera | 06-05-2014 |
20140112979 | METHODS FOR PRODUCING LIPOSOMES - The invention discloses a method for the formation of liposomes by using high shear mixing of aqueous solution of lipid powder; the lipid powder can be produced by any known technique. Components of the liposomes include but are not limited to cationic lipids, immunostimulatory/immunopotentiators and macromolecules as components for the liposome formation. The disclosed method describes the formulation of stable liposomes solitary or complexing high concentrations of macromolecules such as proteins, DNA and RNA having opposite charge of the liposomes by high shear mixing where aggregation is avoided due to the formulation method. | 04-24-2014 |
20130149324 | THERAPEUTIC TB VACCINE - Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis. | 06-13-2013 |
20130095132 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( | 04-18-2013 |
20120208714 | DNA-BASED METHODS FOR CLONE-SPECIFIC IDENTIFICATION OF STAPHYLOCOCCUS AUREUS - MRSA CC398 is a clone of | 08-16-2012 |
20120156282 | EXPANDING THE T CELL REPERTOIRE TO INCLUDE SUBDOMINANT EPITOPES BY VACCINATION WITH ANTIGENS DELIVERED AS PROTEIN FRAGMENTS OR PEPTIDE COCKTAILS - A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves immunizing with pools of overlapping fragments (synthetic peptides, e.g., 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The vaccination with peptide mix induces a T-cell response that includes response to subdominant epitopes is important for protection against chronic disease that on their own induces a response focused only on immunodominant epitopes. | 06-21-2012 |
20120114687 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( | 05-10-2012 |
20120039925 | TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION - The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms ( | 02-16-2012 |
20120014980 | VACCINES COMPRISING TB10.4 - Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4 | 01-19-2012 |
20110287087 | MODIFIED CATIONIC LIPOSOME ADJUVANS - The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of anti-bodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and | 11-24-2011 |
20110250224 | ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES - The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from | 10-13-2011 |
20110229518 | OPTIMIZED INFLUENZA VACCINES - The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These “naked” initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucleotides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g. the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, optionally with the Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from these pandemic influenza virus included, mixed together with DNA or RNA from non-pandemic influenza A as a vaccine against present day and future influenza A viruses. | 09-22-2011 |
20110206713 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the | 08-25-2011 |
20110020387 | MALARIA VACCINE - A fusion protein, from | 01-27-2011 |
20100311041 | PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGI - Dermatophytes which belong to one of the three genera | 12-09-2010 |
20100310585 | THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT - Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from | 12-09-2010 |
20100226975 | Compositions and Methods for Stabilizing Lipid Based Adjuvant Formulations Using Glycolipids - The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable. | 09-09-2010 |
20100160421 | INFLUENZA VACCINES - Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and/or RNA encoding Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and/or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed. | 06-24-2010 |
20090186048 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the | 07-23-2009 |
20080299151 | Influenza vaccines - Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and/or RNA encoding Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and/or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed. | 12-04-2008 |
20080267990 | TB DIAGONOSTIC BASED ON ANTIGENS FROM M. TUBERCULOSIS - The present invention is based on the identification and characterization of a number of novel | 10-30-2008 |